Navigation Links
Celsion Completes Enrollment in Phase I Liver Cancer Study

COLUMBIA, Md.--(BUSINESS WIRE)--May 30, 2007 - CELSION CORPORATION (AMEX:CLN) today announced the completion of its Phase I dose escalation study, using ThermoDox(R), to treat non-resectable liver cancer. The study which was conducted under a Cooperative Research and Development Agreement (CRADA) was performed at the National Cancer Institute (NCI) of the National Institutes of Health, under the leadership of Dr. Steven K. Libutti, Senior Investigator, Head, Tumor Angiogenesis Section, Surgery Branch, Center for Cancer Research, NCI and Dr. Bradford J. Wood, Chief, Interventional Radiology Research at the National Institutes of Health Clinical Center and at Queen Mary Hospital in Hong Kong under the leadership of Dr. Ronnie T. P. Poon, MD, Professor of Surgery, Faculty of Medicine at Queen Mary Hospital, University of Hong Kong.

In the study, a total of 24 primary and metastatic liver cancer patients, with up to 4 lesions ranging from 3 to 7 centimeters, were treated with ThermoDox in combination with radiofrequency ablation at doses ranging from 20 to 60 mg/m2. Enrollment in the study has been completed, and clinical data is currently being assembled for analysis and eventual submission for the FDA. While the Phase I study was designed to determine the maximum safe dose and safety profile of ThermoDox, additional analyses will be undertaken to evaluate any clinical effects achieved during the study.

Michael H. Tardugno, Celsion's President and Chief Executive Officer, commented "Completion of the liver cancer Phase I dosing escalation study represents another milestone in our ThermoDox development program and is consistent with our timelines to initiate our Phase III registrational study for Primary Liver Cancer later this year."

Celsion has licensed the global rights to the temperature-sensitive liposome technology from Duke University where ThermoDox is also being used in a Phase I clinical stu
'"/>




Page: 1 2 3

Related medicine technology :

1. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
2. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
3. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
4. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
5. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Celsion Completes Enrollment Phase Liver Cancer Study
(Date:9/23/2014)... , Sept. 23, 2014  MEDIMETRIKS PHARMACEUTICALS today ... William Resnick have been elected to Medimetriks, ... Mr. Lary, who will serve on Medimetriks, ... investment experience to the Company.  Mr. Lary is ... LLC, a leading institutional investment firm.  Mr. Lary ...
(Date:9/23/2014)... 2014  Vesselon, Inc. today announced the appointment of ... September 15, 2014. Dr. Raths, appointment follows Vesselon,s engagement ... to market a private preferred Series A round to ... "Jurgen,s deep experience across multiple functional areas ... to Vesselon as we develop our device that can ...
(Date:9/23/2014)... 23, 2014  KemPharm, Inc., a clinical-stage specialty ... of proprietary new molecular entity (NME) prodrugs, announced ... (NOL) from Health Canada to begin clinical trials ... lead product candidate KP201 (benzhydrocodone hydrochloride and acetaminophen).  ... acute moderate to moderately severe pain. The Health ...
Breaking Medicine Technology:Medimetriks Pharmaceuticals, Inc. Welcomes Independent Directors Andrew Lary and William Resnick to its Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 3KemPharm Receives Health Canada Approval to Begin KP201 Clinical Trials in Canada 2KemPharm Receives Health Canada Approval to Begin KP201 Clinical Trials in Canada 3
... 7 Genomic Health,Inc. (Nasdaq: GHDX ) ... the,company,s Oncotype DX(R) breast cancer test are scheduled ... Breast Cancer Symposium, taking place,December 13-16, 2007. Oncotype ... to predict the likelihood of recurrence and the ...
... PROCRIT(R) (Epoetin alfa),studies will be presented at the American Society of ... The data will provide important insights including:, ... limiting the use of erythropoiesis-stimulating agents (ESAs) ... -- the use of PROCRIT in extended dosing regimens; ...
Cached Medicine Technology:Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium 2Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium 3PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting 2PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting 3PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting 4PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting 5PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting 6PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting 7PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting 8PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting 9
(Date:9/23/2014)... The Sloane Clinic™, a leading ... Malaysia providing advanced aesthetic dermatology and cosmetic solutions ... impressive skin care repertoire. Specially formulated with super-powered ... the evil forces of aging, acne and photo ... new addition is revolutionizing the way we treat ...
(Date:9/23/2014)... September 23, 2014 The University ... research university located In the Piedmont Triad, announced ... as co-director of the Center for Translational Biomedical ... comes to UNCG after nearly a decade at ... Laboratory, Biological Sciences Division. , “Our goal ...
(Date:9/23/2014)... HealthDay Reporter MONDAY, ... marches demanding action on climate change, a new study ... the United States may soon exacerbate many existing health ... illnesses are expected to increase as the number of ... Patz, director of the Global Health Institute at the ...
(Date:9/23/2014)... Randy Dotinga HealthDay Reporter ... using cholesterol-lowering drugs while in the hospital for a hemorrhagic ... more than four times more likely to survive than people ... People taking the commonly used drugs known as statins ... or to a rehabilitation facility, the study reports. When ...
(Date:9/23/2014)... Hospital Medical Center have published the first study ... published in The Journal of Allergy and ... systemic disorder that has high levels of eosinophils ... series of allergy-associated-immune mechanisms and has a gene ... of a related disorder, eosinophilic esophagitis (EoE). ...
Breaking Medicine News(10 mins):Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 2Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 3Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 4Health News:Former Department of Energy Scientist Joins UNCG as Co-director of Biomedical Research Center 2Health News:Health Woes to Worsen Due to Climate Change, Study Warns 2Health News:Health Woes to Worsen Due to Climate Change, Study Warns 3Health News:Cholesterol-Lowering Drugs May Help After Certain Strokes 2Health News:Cholesterol-Lowering Drugs May Help After Certain Strokes 3Health News:Advancing the understanding of an understudied food allergy disorder 2Health News:Advancing the understanding of an understudied food allergy disorder 3
... well, sports commentators may describe them as being "hot" or ... the eye of the beholder, but a new study by ... that a streak of positive outcomes is likely to continue., ... the study analyzed five years of NBA free throws that ...
... HealthDay Reporter , WEDNESDAY, Oct. 5 (HealthDay News) -- Older ... a greater risk of developing dementia than folks who believe ... the journal Neurology . Someday, "having people rate ... to determine a person,s risk of dementia, especially for people ...
... By Steven Reinberg HealthDay Reporter , WEDNESDAY, Oct. ... forms of multiple sclerosis appears to reduce relapse rates and ... 3 trial. The experimental drug, teriflunomide, is one of ... and may, if approved, be a good choice for many ...
... Oct. 5 (HealthDay News) -- The percentage of nursing ... flu shot is lower than the national goal, and the ... study finds. Brown University researchers examined annual patient records ... 2006-07 to 2008-09. The overall flu vaccination rate for ...
... , WEDNESDAY, Oct. 5 (HealthDay News) -- Nearly one in ... center than 10 years ago due to closures of hospital ... had the greatest impact on black people, the poor, the ... San Francisco researchers. "Trauma centers aren,t just for ,certain, ...
... life experiences -- the ups and downs, and everything in ... emotional set point as adults, according to a new study ... suggests that, in addition to our genes, our life experiences ... "In this time of emphasis on genes for this ...
Cached Medicine News:Health News:Athletes' winning streaks may not be all in our -- or their -- heads 2Health News:Gauging General Health as 'Poor' May Point to Dementia Risk 2Health News:Experimental MS Drug Shows Promise 2Health News:Experimental MS Drug Shows Promise 3Health News:Nursing Homes Not Meeting Flu-Shot Goals, Study Says 2Health News:More Americans Face Longers Trips to ER 2Health News:Virginia Commonwealth University study: We are what we experience 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: